South Korea · Delayed Price · Currency is KRW Boditech Med Statistics
Total Valuation
Boditech Med has a market cap or net worth of KRW 211.59 billion. The enterprise value is 182.57 billion.
| Market Cap | 211.59B |
| Enterprise Value | 182.57B |
Important Dates
The next estimated earnings date is Wednesday, August 12, 2026.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | Mar 31, 2026 |
Share Statistics
Boditech Med has 20.34 million shares outstanding. The number of shares has decreased by -1.14% in one year.
| Current Share Class | 20.34M |
| Shares Outstanding | 20.34M |
| Shares Change (YoY) | -1.14% |
| Shares Change (QoQ) | +1.19% |
| Owned by Insiders (%) | 35.97% |
| Owned by Institutions (%) | 1.13% |
| Float | 12.91M |
Valuation Ratios
The trailing PE ratio is 8.66.
| PE Ratio | 8.66 |
| Forward PE | n/a |
| PS Ratio | 1.28 |
| PB Ratio | 0.83 |
| P/TBV Ratio | 0.89 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 10.26 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 7.02 |
| EV / Sales | 1.10 |
| EV / EBITDA | 4.92 |
| EV / EBIT | 6.76 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.55, with a Debt / Equity ratio of 0.05.
| Current Ratio | 5.55 |
| Quick Ratio | 3.69 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 0.36 |
| Debt / FCF | -0.89 |
| Interest Coverage | 55.98 |
Financial Efficiency
Return on equity (ROE) is 10.84% and return on invested capital (ROIC) is 10.66%.
| Return on Equity (ROE) | 10.84% |
| Return on Assets (ROA) | 6.23% |
| Return on Invested Capital (ROIC) | 10.66% |
| Return on Capital Employed (ROCE) | 10.29% |
| Weighted Average Cost of Capital (WACC) | 6.07% |
| Revenue Per Employee | 306.54M |
| Profits Per Employee | 48.04M |
| Employee Count | 541 |
| Asset Turnover | 0.60 |
| Inventory Turnover | 1.61 |
Taxes
In the past 12 months, Boditech Med has paid 4.93 billion in taxes.
| Income Tax | 4.93B |
| Effective Tax Rate | 15.89% |
Stock Price Statistics
The stock price has decreased by -35.02% in the last 52 weeks. The beta is 0.37, so Boditech Med's price volatility has been lower than the market average.
| Beta (5Y) | 0.37 |
| 52-Week Price Change | -35.02% |
| 50-Day Moving Average | 11,235.20 |
| 200-Day Moving Average | 12,875.30 |
| Relative Strength Index (RSI) | 39.54 |
| Average Volume (20 Days) | 57,079 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Boditech Med had revenue of KRW 165.84 billion and earned 25.99 billion in profits. Earnings per share was 1,200.41.
| Revenue | 165.84B |
| Gross Profit | 96.45B |
| Operating Income | 27.67B |
| Pretax Income | 31.05B |
| Net Income | 25.99B |
| EBITDA | 37.81B |
| EBIT | 27.67B |
| Earnings Per Share (EPS) | 1,200.41 |
Balance Sheet
The company has 56.25 billion in cash and 13.74 billion in debt, with a net cash position of 42.52 billion or 2,089.76 per share.
| Cash & Cash Equivalents | 56.25B |
| Total Debt | 13.74B |
| Net Cash | 42.52B |
| Net Cash Per Share | 2,089.76 |
| Equity (Book Value) | 255.10B |
| Book Value Per Share | 11,136.42 |
| Working Capital | 123.55B |
Cash Flow
In the last 12 months, operating cash flow was 20.63 billion and capital expenditures -36.07 billion, giving a free cash flow of -15.44 billion.
| Operating Cash Flow | 20.63B |
| Capital Expenditures | -36.07B |
| Depreciation & Amortization | 10.14B |
| Net Borrowing | 5.10B |
| Free Cash Flow | -15.44B |
| FCF Per Share | -758.94 |
Margins
Gross margin is 58.16%, with operating and profit margins of 16.69% and 15.67%.
| Gross Margin | 58.16% |
| Operating Margin | 16.69% |
| Pretax Margin | 18.72% |
| Profit Margin | 15.67% |
| EBITDA Margin | 22.80% |
| EBIT Margin | 16.69% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 150.00, which amounts to a dividend yield of 1.43%.
| Dividend Per Share | 150.00 |
| Dividend Yield | 1.43% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 12.50% |
| Buyback Yield | 1.14% |
| Shareholder Yield | 2.62% |
| Earnings Yield | 12.28% |
| FCF Yield | -7.30% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 5, 2017. It was a forward split with a ratio of 1.1.
| Last Split Date | Apr 5, 2017 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
Boditech Med has an Altman Z-Score of 6.78 and a Piotroski F-Score of 5.
| Altman Z-Score | 6.78 |
| Piotroski F-Score | 5 |